– Durability of Response and Continued Manageable Safety Profile for the Phase 1 and iMMagine-1 Studies with Anito-cel in Patients with Relapsed/Refractory Multiple Myeloma to be Presented by Partner ...
BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration ...
– Kite Cell Therapy Business Unit at Gilead Sciences K.K. Will Manage the Sales and Promotion Activities in Japan After the Marketing Authorization Transfer – SANTA MONICA, Calif. & TOKYO--(BUSINESS ...
The American Cancer Society today announced an expanded effort to improve access to help more people with blood cancers ...
– ZUMA-5 Analysis Shows Median Progression-Free Survival of 62.2 Months and Median Duration of Response of 60.4 Months After Median Follow-Up of More Than Five Years – – Over Half of Patients Alive at ...
American Cancer Society to help people with blood cancers access CAR T-cell therapy through a renewed programme supported by Kite: Atlanta Saturday, June 27, 2026, 16:00 Hrs [IST] ...
Cencora (NYSE:COR) has entered a major U.S. distribution partnership with Kite Pharma, a Gilead company. The agreement focuses on market access and distribution support for FDA approved CAR T cell ...
Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite’s U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ...
Gilead Sciences broke into the field of cancer cell therapies through an acquisition. Now it’s aiming to be part of the next generation of such therapies by buying clinical-stage Interius ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results